Literature DB >> 8557324

Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

M R Lagranderie1, A M Balazuc, E Deriaud, C D Leclerc, M Gheorghiu.   

Abstract

Among the various parameters which may contribute to Mycobacterium bovis BCG vaccination efficiency, the choice of the vaccine strain may play an important role. In the present study, we therefore compared the immunogenicity of five different BCG strains that are commonly used for BCG vaccine production (Glaxo 1077, Japanese 172, Pasteur 1173P2, Prague, and Russian strains). The comparison of the growth capacity of these BCG strains in BALB/c and C3H mice demonstrated that a great difference exists between the capacity of various BCG strains to multiply and persist in target organs. A much lower recovery of BCG could be shown in mice immunized with Prague and Japanese BCG strains. T-cell responses of BCG-immunized mice were also examined by analyzing T-cell proliferative responses, cytokine production, delayed-type hypersensitivity responses, and cytotoxic activity. All these assays demonstrated that BCG immunization induced strong CD4+ T-cell responses, mostly of the Th1 type, as demonstrated by interleukin-2 and gamma interferon production. These studies also demonstrated that there are differences between BCG strains in stimulating these T-cell responses. A lack of induction of cytotoxic activity was observed following immunization with the Japanese strain. Lower anti-purified protein derivative antibody responses were also observed after intravenous or oral immunization with this BCG strain. Finally, the protective activity of these BCG strains was tested by measuring the capacity of immunized mice to eliminate recombinant Pasteur and Japanese BCG strains which expressed beta-galactosidase. The results of these experiments clearly demonstrated that the Prague and Japanese strains were unable to protect mice against a second mycobacterial challenge whereas mice immunized with the Glaxo, Pasteur, or Russian strain eliminated the recombinant BCG very efficiently. Altogether, the results of the present study strongly support the view that there are considerable differences in the immunogenicity of various BCG vaccine strains and that these differences may play a major role in BCG vaccination efficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557324      PMCID: PMC173719          DOI: 10.1128/iai.64.1.1-9.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness.

Authors:  R J DUBOS; C H PIERCE
Journal:  Am Rev Tuberc       Date:  1956-11

2.  Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages.

Authors:  G A Rook; J Steele; M Ainsworth; B R Champion
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

3.  Genetic control of resistance to mycobacterial infection.

Authors:  E Skamene
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

4.  Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs.

Authors:  D Smith; G Harding; J Chan; M Edwards; J Hank; D Muller; F Sobhi
Journal:  J Biol Stand       Date:  1979-07

5.  Report on results of a collaborative assay of BCG vaccines organized by the International Associaton of Biological Standardization.

Authors:  V M Sekhuis; H Freudenstein; J L Sirks
Journal:  J Biol Stand       Date:  1977

Review 6.  Cellular immunity.

Authors:  G B Mackaness; R V Blanden
Journal:  Prog Allergy       Date:  1967

7.  Changes in BCG strains.

Authors:  T W Osborn
Journal:  Tubercle       Date:  1983-03

8.  Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains.

Authors:  M Gheorghiu; P H Lagrange
Journal:  Ann Immunol (Paris)       Date:  1983 Jan-Feb

9.  The BCG controversy. A methodological and statistical reappraisal.

Authors:  J D Clemens; J J Chuong; A R Feinstein
Journal:  JAMA       Date:  1983-05-06       Impact factor: 56.272

10.  Mycolic acid patterns of four vaccine strains of Mycobacterium bovis BCG.

Authors:  D E Minnikin; S M Minnikin; G Dobson; M Goodfellow; F Portaels; L van den Breen; D Sesardic
Journal:  J Gen Microbiol       Date:  1983-03
View more
  54 in total

1.  Evaluation of spoligotyping in a study of the transmission of Mycobacterium tuberculosis.

Authors:  Y O Goguet de la Salmonière; H M Li; G Torrea; A Bunschoten; J van Embden; B Gicquel
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 2.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro.

Authors:  Ana M Aguirre-Blanco; Pauline T Lukey; Jacqueline M Cliff; Hazel M Dockrell
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

4.  Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes.

Authors:  M Abolhassani; M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.

Authors:  Cesar Boggiano; Katrin Eichelberg; Lakshmi Ramachandra; Jaqueline Shea; Lalita Ramakrishnan; Samuel Behar; Joel D Ernst; Steven A Porcelli; Markus Maeurer; Hardy Kornfeld
Journal:  Vaccine       Date:  2017-05-02       Impact factor: 3.641

7.  Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex.

Authors:  J Magdalena; P Supply; C Locht
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains.

Authors:  M Carmen Garcia Pelayo; Swapna Uplekar; Andrew Keniry; Pablo Mendoza Lopez; Thierry Garnier; Javier Nunez Garcia; Laura Boschiroli; Xiangmei Zhou; Julian Parkhill; Noel Smith; R Glyn Hewinson; Stewart T Cole; Stephen V Gordon
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

9.  Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model.

Authors:  S M Irwin; A Goodyear; A Keyser; R Christensen; J M Troudt; J L Taylor; A Bohsali; V Briken; A A Izzo
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

10.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.